NEW YORK, May 1, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ITCI). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/itci.
The investigation concerns whether Intra-Cellular and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Intra-Cellular is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS).
Intra-Cellular is presently developing ITI-007 (lumaterperone) as a schizophrenia treatment. On August 4, 2016, Intra-Cellular's CEO Sharon Mates specified during an earnings call that "our studies to-date supports the efficacy and safety of ITI-007 for the treatment of schizophrenia." Then on May 1, 2017, Intra-Cellular revealed that U.S. Food and Drug Administration had requested further information to verify that the findings observed in nonclinical animal toxicology studies of lumateperone are not suggestive of a safety risk associated with long term exposure in humans. Following this news, Intra-Cellular stock dropped during intraday trading on May 1, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of Intra-Cellular, you can assist this investigation by visiting the firm's site: www.bgandg.com/itci. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-intra-cellular-therapies-inc-itci-300448805.html
SOURCE Bronstein, Gewirtz & Grossman, LLC